An interventional study of PK Papyrus Covered Coronary Stent System in Coronary Disease, sponsored by Methodist Health System. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Methodist Health System · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 274 studies in Coronary Disease with a site in United States — 12 open to participants now, 23 under way, 2 of them phase 3. Coronary Disease · United States.
Among the 274 studies in Coronary Disease with a site in United States, this one is the 147th largest by planned enrollment of the 184 interventional ones that give a count, is one of 3 that started in 2023, is one of 78 with no phase, reaches primary completion later than 12 of the 22 other live ones, and was the 254th registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →12 of the 274 studies in Coronary Disease with a site in United States are open now. Recruiting first, the newest first:
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
Amgen · Sites in United States, Australia, Canada and 1 more country
Ages 50–105
West Virginia School of Osteopathic Medicine · Sites in United States
Ages 18–64
University of California, Los Angeles · Sites in United States
Ages 60–80
Weill Medical College of Cornell University · Sites in United States, Austria, Canada and 3 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
274 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 43 · Phase 3 36 · Phase 4 18
First in 1973; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 41 is below the median of 160 across 780 interventional studies indexed under Coronary Disease.
Median enrollment 200 across the 184 interventional studies, 324 across the 87 observational. Of the 235 that completed or were terminated, 88 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 274 have an industry lead sponsor. The 10 most frequent:
Methodist Health System is the lead sponsor of 170 studies on the registry; 50 are open to participants now.
Methodist Health System has 1 study filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Coronary Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997693Phase 3Weill Medical College of Cornell UniversityOne-Month DAPT in CABG Patients | 2027-01 |
| NCT02694094Johns Hopkins UniversityImpact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | 2026-12 |
| NCT06170541Johns Hopkins UniversityCORE-COMPARE Pilot Study | 2026-12 |
| NCT05918380University Hospitals Cleveland Medical CenterProject 3: ACHIEVE- CHD | 2027-01-01 |
| NCT00406185Intermountain Health Care, Inc.Database Registry of the Intermountain Heart Collaborative Study | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 274 studies in Coronary Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The PK Papyrus Covered Coronary Stent System is a coronary stent being used at Methodist Dallas Medical Center for patients with coronary perforations.
The FDA has approved the PK Papyrus Covered Coronary Stent System for use in patients being treated for acute perforations of native coronary arteries and coronary bypass grafts in vessels ranging from 2.5 to 5.0 mm in diameter, under a Humanitarian Device Exemption (HDE #H170004). Methodist Dallas Medical Center will use this device for treating the above-described patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
Device: PK Papyrus Covered Coronary Stent System
PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
Determining the number of the unanticipated adverse events related to the use of PK Papyrus Coronary Stent Graft System
Number of patients with PK Papyrus being treated for acute perforations of native coronary arteries and bypass grafts in vessels.
Time frame: Up to 10 years
Number of patients with the device
number of patients with success coronary artery and bypass grafts
Time frame: 10 years
Started Aug 2023 (actual). Primary completion is estimated for Aug 2027, 48 months after the start.
Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 48 months is above that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.